Ignite Creation Date:
2024-05-05 @ 11:57 PM
Last Modification Date:
2024-10-26 @ 10:42 AM
Study NCT ID:
NCT01455389
Status:
TERMINATED
Last Update Posted:
2022-03-02
First Post:
2011-10-17
Brief Title:
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Sponsor:
Genprex Inc
Organization:
Genprex Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Lung Cancer |
Keywords:
| Name | View |
|---|---|
| PK | View |
| Lung Cancer | View |
| Non-small cell lung cancer | View |
| NSCLC | View |
| FUS1-nanoparticles | View |
| DOTAPChol-TUSC2 | View |
| DOTAPCholesterol-TUSC2 Liposome Complex | View |
| Erlotinib | View |
| Erlotinib Hydrochloride | View |
| OSI-774 | View |
| Tarceva | View |
| Dexamethasone | View |
| Decadron | View |
| Diphenhydramine | View |
| Benadryl | View |
| Benylin Cough SyrupPharmacokinetic | View |